Targeted signal transduction therapies in myeloid malignancies (Q37784447)

23 August 2017

title

Targeted signal transduction therapies in myeloid malignancies (English)

1 reference

23 August 2017

2

Elizabeth Hexner

1 reference

23 August 2017

Emma Scott

1

1 reference

23 August 2017

Alexander Perl

series ordinal

3

1 reference

23 August 2017

Martin Carroll

series ordinal

4

1 reference

23 August 2017

Elizabeth Hexner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20809224

4 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20809224

4 July 2024

publication date

1 November 2010

1 reference

full work available at URL

23 August 2017

http://www.current-reports.com/1523-3790/12/358

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20809224

4 July 2024

published in

Current Oncology Reports

1 reference

23 August 2017

volume

12

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

358-365

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34 human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

FLT3: ITDoes matter in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11912-010-0126-Z

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

12 December 2020

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

12 December 2020

Some speculations on the myeloproliferative syndromes.

1 reference

12 December 2020

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

1 reference

12 December 2020

DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups

1 reference

12 December 2020

FLT3 mutations: biology and treatment

1 reference

12 December 2020

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

10.1007/S11912-010-0126-Z

Identifiers

DOI

1 reference

23 August 2017

1 reference